Outpatient treatment of community acquired venous thromboembolism - The Christchurch experience

New Zealand Medical Journal

Volumn 115, Issue 1158, 2002, Pages

  Heaton, David ^a   Han, Dug Yeo ^a   Inder, Alison ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; BLEEDING DISORDER; BODY WEIGHT; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DISEASE COURSE; DRUG DOSE REGIMEN; EPISTAXIS; FEMALE; HEALTH CARE DELIVERY; HEMOSTASIS; HOSPITAL SERVICE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; OUTPATIENT CARE; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; VENOUS THROMBOEMBOLISM; ADOLESCENT; AMBULATORY CARE; DRUG COMBINATION; EVALUATION; LUNG EMBOLISM; MIDDLE AGED; OUTPATIENT DEPARTMENT; RISK FACTOR; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTICOAGULANTS; DALTEPARIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NEW ZEALAND; OUTPATIENT CLINICS, HOSPITAL; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS; WARFARIN;

EID: 0037178930     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
2. Simonneau G, Sors H, Charbonnier B et al for The Thésée Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-9.
3. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-62.
4. Mattiasson I, Berntorp E, Bornhov S et al. Out-patient treatment of acute deep vein thrombosis. Int Angiol 1998; 17: 146-50.
5. Fennerty A, Dolben J, Thomas P et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. B M J 1984; 288: 1268-70.
6. Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
7. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000; 160: 809-15.
8. Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. Brit J Haematol 2001; 114: 512-28.
9. De Stefano V, Martinelli I, Mannucci PM et al. The risk of recurrent deep vein thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801-6.
10. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dose of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001; 31: 42-8.
11. Holford NHG. Choosing the first dose. New Ethicals 1990; 27: 73-80.
12. Crowther MA, Ginsberg JB, Kearon C et al. A randomised trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159: 46-8.
13. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. J Intern Med 1996; 240: 395-401.
14. Egermayer P, Inder A, Town GI. The use of warfarin in Christchurch for the treatment of venous thromboembolism. N Z Med J 2001; 114: 336-8.